Clinical Trial Update: Simvastatin + Cetuximab/Irinotecan in K-ras Mutant Colorectal Cancer (CRC) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluated the combination of simvastatin with cetuximab and irinotecan for KRAS-mutant metastatic colorectal cancer; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Camptosar (irinotecan)
• ERBITUX (cetuximab)
• SIMVASTATIN (SIMVASTATIN)

Snippet

Sponsor: Samsung Medical Center | Conditions: Metastatic Colorectal Cancer | Phase 2 | Status: COMPLETED